Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F C Thistlethwaite

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
British Journal of Cancer|October 28, 2005
Engineering T cells for cancer therapyW Mansoor, D E Gilham, F C Thistlethwaite, et al.
European Journal of Gynaecological Oncology|July 13, 2007
Weekly paclitaxel in the treatment of recurrent ovarian carcinomaL Byrd, F C Thistlethwaite, A Clamp, et al.
Molecular Cell|August 13, 1999
Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2H Lee, A H Trainer, L S Friedman, et al.
Molecular Cell|July 14, 1998
Involvement of Brca2 in DNA repairK J Patel, V P Yu, H Lee, et al.
British Journal of Cancer|June 24, 2024
Social determinants of health inequalities in early phase clinical trials in Northern EnglandS Rae, S Shaya, E Taylor, et al.
Cancer Research|April 16, 1998
Thymic lymphomas in mice with a truncating mutation in Brca2L S Friedman, F C Thistlethwaite, K J Patel, et al.
ESMO Open|August 22, 2022
EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patientsP Jittla, D M Graham, C Zhou, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
British Journal of Cancer|October 28, 2005
Engineering T cells for cancer therapyW Mansoor, D E Gilham, F C Thistlethwaite, et al.
European Journal of Gynaecological Oncology|July 13, 2007
Weekly paclitaxel in the treatment of recurrent ovarian carcinomaL Byrd, F C Thistlethwaite, A Clamp, et al.
Molecular Cell|August 13, 1999
Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2H Lee, A H Trainer, L S Friedman, et al.
Molecular Cell|July 14, 1998
Involvement of Brca2 in DNA repairK J Patel, V P Yu, H Lee, et al.
British Journal of Cancer|June 24, 2024
Social determinants of health inequalities in early phase clinical trials in Northern EnglandS Rae, S Shaya, E Taylor, et al.
Cancer Research|April 16, 1998
Thymic lymphomas in mice with a truncating mutation in Brca2L S Friedman, F C Thistlethwaite, K J Patel, et al.
ESMO Open|August 22, 2022
EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patientsP Jittla, D M Graham, C Zhou, et al.
Pageof 1